To the editor:

We are greatly encouraged to read the report by Bernaudin et al,1  showing excellent outcomes for children and adolescents receiving myeloablative allogeneic bone marrow transplantation (BMT) for sickle cell disease (SCD). Approximately 200 children worldwide have undergone BMT after myeloablative conditioning with busulfan and cyclophosphamide, with or without antithymocyte globulin, with a follow-up period approaching 10 years.1-3  With this experience, outcome has improved with an event free survival of 95% in the most recent patient cohort, and children undergoing BMT can now reasonably expect to be cured of SCD.

The reports to date contain valuable information including rates of engraftment, graft rejection, graft-versus-host disease (GVHD), and cerebral vascular complications; however, details regarding the late effects of BMT in this population are lacking (Table 1). While some complications are well known,4  patients with SCD may be more susceptible to or more burdened by such complications given the legacy of organ damage from their underlying disease. For example, the authors describe that 11% of patients experienced “mild forms” of chronic GVHD, and that 2.4% had extensive chronic GVHD. The mild forms were not described, nor was organ involvement delineated. Because SCD and busulfan may lead to pulmonary toxicity, a more detailed description of chronic GVHD, potentially including objective measures such as pulmonary function tests, would be helpful to assess the risk of developing late pulmonary complications. The authors also reported that “2 years after transplantation, the mean height was unchanged.” Did the children grow normally as in other reports?5-7  In addition, busulfan is toxic to gonadal tissue, and hypergonadotropic hypogonadism is very frequent after myeloablative BMT.6,8  This cause of primary amenorrhea (ovarian failure) is assumed in the prepubertal girls reported, but no data on LH, FSH, or estrogen levels were provided. In boys, the Sertoli cells (responsible for spermatogenesis) are more easily damaged than Leydig cells (responsible for testosterone production), thus having normal testosterone, LH, and FSH levels does not ensure normal gonadal function.6,8  In fact, testicular size and semen analysis better predict gonadal function and fertility potential. There are also incomplete descriptions of treatment related outcomes, such as cataracts and secondary malignancy, or other long-term outcomes for which underlying SCD could alter the long-term consequences, such as renal and neurocognitive function.

Table 1

Late effects of BMT in SCD

Bernaudin et al1 Vermylen et al,2  Brachet et al6 Eggleston et al,5  Walters et al9 Socie et al,4  Ade et al10 
Pulmonary function Not reported Bronchiolitis obliterans in 2 Stable compared to baseline at least up to 3 years after BMT Restrictive defects are frequent at 3-6 months; obstructive defects are seen in 20% of patients, usually associated with cGVHD 
Growth curve “No change in mean height” Normal or improved except in 2 with cGVHD Normal if BMT was done before or after puberty5  1 standard deviation score below mean height and weight in TBI based BMT; near normal mean height and weight in chemo-based BMT 
Gonadal function Male: age appropriate testosterone, LH and FSH levels. Female: primary amenorrhea in many; secondary amenorrhea in 7 Male: normal sexual maturation; small testes in all, oligospermia in 1, azospermia in another. Female: ovarian failure in 7, recovery in 2 others Male: not reported. Female: ovarian failure in 4, recovery in 2 others Male: significant reduction in spermatogenesis despite normal testosterone level. Onset of puberty usually not affected. Younger age at transplantation may have lower testicular volume and function. Female: hypergonadotrophic hypogonadism is common. Younger age at transplantation has better chance of ovarian recovery. 
Late malignancy Not reported Not reported Not reported PTLD (1% at 10 years), solid tumors (2% at 10 years); lymphoma (rare), leukemia (rare) 
Neurocognitive testing Not reported Not reported Not reported 20% of patients reported problems with memory in the first year after BMT; 10% have cognitive impairment; possible lower IQ levels 
Bernaudin et al1 Vermylen et al,2  Brachet et al6 Eggleston et al,5  Walters et al9 Socie et al,4  Ade et al10 
Pulmonary function Not reported Bronchiolitis obliterans in 2 Stable compared to baseline at least up to 3 years after BMT Restrictive defects are frequent at 3-6 months; obstructive defects are seen in 20% of patients, usually associated with cGVHD 
Growth curve “No change in mean height” Normal or improved except in 2 with cGVHD Normal if BMT was done before or after puberty5  1 standard deviation score below mean height and weight in TBI based BMT; near normal mean height and weight in chemo-based BMT 
Gonadal function Male: age appropriate testosterone, LH and FSH levels. Female: primary amenorrhea in many; secondary amenorrhea in 7 Male: normal sexual maturation; small testes in all, oligospermia in 1, azospermia in another. Female: ovarian failure in 7, recovery in 2 others Male: not reported. Female: ovarian failure in 4, recovery in 2 others Male: significant reduction in spermatogenesis despite normal testosterone level. Onset of puberty usually not affected. Younger age at transplantation may have lower testicular volume and function. Female: hypergonadotrophic hypogonadism is common. Younger age at transplantation has better chance of ovarian recovery. 
Late malignancy Not reported Not reported Not reported PTLD (1% at 10 years), solid tumors (2% at 10 years); lymphoma (rare), leukemia (rare) 
Neurocognitive testing Not reported Not reported Not reported 20% of patients reported problems with memory in the first year after BMT; 10% have cognitive impairment; possible lower IQ levels 

As clinicians begin to recommend myeloablative BMT to children with SCD more routinely in the absence of current major complications based upon these encouraging results, long-term outcome data will be an essential part of the decision-making process. Perhaps the assembled experience of those involved in BMT for SCD could be combined to make such outcomes available to the clinicians, and ultimately, the affected patients.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Matthew M. Hsieh, National Heart, Lung, and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bldg 10, 9N 116, Bethesda, MD 20892; e-mail: [email protected].

1
Bernaudin
 
F
Socie
 
G
Kuentz
 
M
et al. 
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.
Blood
2007
, vol. 
110
 (pg. 
2749
-
2756
)
2
Vermylen
 
C
Cornu
 
G
Ferster
 
A
et al. 
Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.
Bone Marrow Transplant
1998
, vol. 
22
 (pg. 
1
-
6
)
3
Walters
 
MC
Patience
 
M
Leisenring
 
W
et al. 
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.
Biol Blood Marrow Transplant
2001
, vol. 
7
 (pg. 
665
-
673
)
4
Socié
 
G
Salooja
 
N
Cohen
 
A
et al. 
Nonmalignant late effects after allogeneic stem cell transplantation.
Blood
2003
, vol. 
101
 (pg. 
3373
-
3385
)
5
Eggleston
 
B
Patience
 
M
Edwards
 
S
et al. 
Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia.
Br J Haematol
2007
, vol. 
136
 (pg. 
673
-
676
)
6
Brachet
 
C
Heinrichs
 
C
Tenoutasse
 
S
Devalck
 
C
Azzi
 
N
Ferster
 
A
Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation.
J Pediatr Hematol Oncol
2007
, vol. 
29
 (pg. 
445
-
450
)
7
Cohen
 
A
Rovelli
 
A
Bakker
 
B
et al. 
Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT.
Blood
1999
, vol. 
93
 (pg. 
4109
-
4115
)
8
Cicognani
 
A
Pasini
 
A
Pession
 
A
et al. 
Gonadal function and pubertal development after treatment of a childhood malignancy.
J Pediatr Endocrinol Metab
2003
, vol. 
16
 
Suppl 2
(pg. 
321
-
326
)
9
Walters
 
MC
Storb
 
R
Patience
 
M
et al. 
Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease.
Blood
2000
, vol. 
95
 (pg. 
1918
-
1924
)
10
Adès
 
L
Guardiola
 
P
Socie
 
G
Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems.
Blood Rev
2002
, vol. 
16
 (pg. 
135
-
146
)
Sign in via your Institution